Global Biologics Contract Development Market Size, Trends & Growth Opportunity, By Source (Microbial, Mammalian, and Others), By Product Service (Cell Line Development, Process Development, Product, and Others), By Disease Indication,  By Region and Forecast till 2027
Global Biologics Contract Development Market
The global Biologics Contract Development market was valued at US$ 9.93 billion in 2021 and it is expected to reach at US$ 18.15 billion in 2027 at a CAGR of 10.8 % during forecast period 2022-2027.
Biologics contract development organizations provide complete services from cell line development to long term commercial supply of biological products. They offer various services including development of cell lines, analytical and bio-analytical methods, upstream and downstream processes, and formulations and quality assessment. This is type of outsourcing where manufacturer enters into formal agreement with another manufacturing organization for its parts, components, and products.  
Market Drivers
Rise in adoption of advanced technologies for biological production is the key driving factor which is expected to boost the global biologics contract development market growth. Furthermore, Increase in outsourcing of research and development activities by pharma and bio-pharma companies and favorable regulatory environment for clinical trials in developing nations will positively contribute the market growth. Moreover, increase in number of mergers and collaborations will propel the market growth. For instance, in March 2019, Thermo Fischer Scientific had announced that it will acquire Brammer Bio, which is leading viral vector contract developer for cell and gene therapies. The main aim of this acquisition is strengthen its product portfolio in the area of gene therapy.  In addition to that, increase in prevalence of various diseases such as cancer, neurological disorders, and cardiovascular diseases will fuel the market growth. For instance, as per the World Health Organization (WHO) approximately 8.2 million people die each year due to cancer worldwide. Many biologics contract organizations are now shifting to Single Use Bioreactors that offer lower up front capital costs, improved throughputs, and greater manufacturing flexibility will drive the biologicas contract development market growth.
Market Restraints
However, change in trade policies between countries is the major challenging factor which is expected to hinder the global biologics contract development market growth during this analysis period.
Covid-19 Impact 
Due to outbreak of covid -19 as public emergency and pandemic declared there is increase in demand for medical supplies,the devices like atomizers,life-support machines,oxygen generators,PPE kit which significantly impact the market growth.
Recent Development 
In 2021, Almac Group launch of biologics contract of testing and development solutions which helps in development and testing of new biologics products.In 2020, Lake Pharma In, launch integrated chemistry and biologics services for streamlined antibody- drug conjugates development solutions for pharmaceutical and biotechnology sectors.

Market Segmentation
Global Biologics Contract Development Market is segmented into source such as Microbial, Mammalian, and Others, by product service such as Cell Line Development, Process Development (Upstream, and Downstream), product ( MABs, Recombinant Proteins, and Others), and Others. Further, market is segmented into disease indication such as Oncology, Immunological Disorder, Cardiovascular Disorder, Hematological Disorder, and Others.
Also, Global Biologics Contract Development Market is segmented into five regions such as North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.
Market Key Players
Various key players are discussed in this report such as WuXi Biologics, Fujifilm Diosynth Biotechnologies, Abzena Ltd., AGC Biologics, KBI Biopharma, SE Thermo Fisher (Patheon), LakePharma, Genscript Biotech Corporation, Bionova Scientific, and Boehringer Ingelheim BioXcellence
Market Taxonomy
By Source
• Microbial
• Mammalian
• Others
By Product Service
• Cell Line Development
• Process Development
o Upstream
o Downstream
• Product 
o  MABs
o Recombinant Proteins
o  Others
• Others
By Disease Indication
• Oncology
• Immunological Disorder
• Cardiovascular Disorder
• Hematological Disorder
• Others
By Region
• North America
• Latin America
• Europe
• Asia Pacific
• Middle East & Africa

Key Questions Addressed by the Report
• What are the Key Opportunities in Global Biologics Contract Development Market?
• What will be the growth rate from 2022 to 2027?
• Which segment/region will have highest growth?
• What are the factors that will impact/drive the Market?
• What is the competitive Landscape in the Industry?
• What is the role of key players in the value chain?
• What are the strategies adopted by key players?

Global Biologics Contract Development Market 
1 Introduction 
1.1 Objective of the Study
1.2 Market definition
1.3 Market Scope
2 Research Methodology
2.1 Data Mining
2.2 Validation
2.3 Primary Interviews
2.4 List of Data Sources
3 Executive Summary
4 Global Biologics Contract Development Market Outlook
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis
5 Global Biologics Contract Development Market, By Source
5.1 Y-o-Y Growth Comparison, By Source 
5.2 Global Biologics Contract Development Market Share Analysis, By Source 
5.3 Global Biologics Contract Development Market Size and Forecast, By Source
5.3.1 Microbial
5.3.2. Mammalian
5.3.3 Others
6 Global Biologics Contract Development Market, By Product Service
6.1 Y-o-Y Growth Comparison, By Product Service
6.2 Global Biologics Contract Development Market Share Analysis, By Product Service
6.3 Global Biologics Contract Development Market Size and Forecast, By Product Service
6.3.1Cell Line Development
6.3.2 Process Development
6.2.2.1 Upstream
6.2.2.2 Downstream
6.3.3. Product
6.3.3.1 MABs
6.3.3.2. Recombinant Process
6.3.3.3. Others
6.3.3.3. Others
7 Global Biologics Contract Development Market, By Diseases Indication
7.1 Y-o-Y Growth Comparison, By Diseases Indication
7.2 Global Biologics Contract Development Market Share Analysis, By Diseases Indication
7.3 Global Biologics Contract Development Market Size and Forecast, By Diseases Indication
7.3. 1 Oncology 
7.3.2. Immunological Disorder
7.3.3. Cardiovascular Disorder
7.3.4. Hematological Disorder
7.3.5. Others
8Global Biologics Contract Development Market, By Region
8.1 Global Biologics Contract Development Market Share Analysis, By Region
8.2 Global Biologics Contract Development Market Share Analysis, By Region
8.3 Global Biologics Contract Development Market Size and Forecast, By Region
9 North America Biologics Contract Development Market Analysis and Forecast (2022-2027)
9.1 Introduction
9.2 North America Biologics Contract Development Market Share Analysis, By Source
9.3 North America Biologics Contract Development Market Size and Forecast, By Product Service
9.4 North America Biologics Contract Development Market Size and Forecast, By Diseases Indication
9.5 North America Biologics Contract Development Market Size and Forecast, By Country
9.5.1 U.S.
9.5.2 Canada
9.5.3 Mexico
10EuropeBiologics Contract Development Market Analysis and Forecast (2022-2027)
10.1 Introduction
10.2 Europe Biologics Contract Development Market Share Analysis, By Source 
10.3 Europe Biologics Contract Development Market Size and Forecast, By Product Service 
10.4 Europe Biologics Contract Development Market Size and Forecast, By Diseases Indication
10.5 Europe Biologics Contract Development Market Size and Forecast, By Country
10.5.1 Germany
10.5.2 France
10.5.3 UK
10.54. Rest of Europe
11Asia Pacific Biologics Contract Development Market Analysis and Forecast (2022-2027)
11.1 Introduction
11.2 Asia Pacific Biologics Contract Development Market Share Analysis, By Source 
11.3 Asia Pacific Biologics Contract Development Market Size and Forecast, By Product Service 
11.4 Asia Pacific Biologics Contract Development Market Size and Forecast, By Diseases Indication
11.5 Asia Pacific Biologics Contract Development Market Size and Forecast, By Country
11.5.1 China 
11.5.2 Japan
11.5.3 India
11.5.4. Rest of Asia Pacific
12Latin America Biologics Contract Development Market Analysis and Forecast (2022-2027)
12.1 Introduction
12.2 Latin America Biologics Contract Development Market Share Analysis, By Source 
12.3 Latin America Biologics Contract Development Market Size and Forecast, By Product Service 
12.4 Latin America Biologics Contract Development Market Size and Forecast, By Diseases Indication
12.5 Latin America Biologics Contract Development Market Size and Forecast, Country
13Middle East Biologics Contract Development Market Analysis and Forecast (2022-2027)
13.1 Introduction
 13.2 Middle East Biologics Contract Development Market Share Analysis, By Source 
13.3 Middle East Biologics Contract Development Market Size and Forecast, By Product Service 
13.4 Middle East Biologics Contract Development Market Size and Forecast, By Diseases Indication
13.5 Middle East Biologics Contract Development Market Size and Forecast, By Country
14Competitive Analysis
14.1 Competition Dashboard
14.2 Market share Analysis of Top Vendors
14.3 Key Development Strategies
15Company Profiles
15.1 WuXi Biologics 
15.1.1 Overview
15.1.2 Offerings
15.1.3 Key Financials
15.1.4 Business Segment & Geographic Overview
15.1.5 Key Market Developments
15.1.6 Key Strategies
15.2. Fujifilm Diosynth Biotechnologies
15.2.1 Overview
15.2.2 Offerings
15.2.3 Key Financials
15.2.4 Business Segment & Geographic Overview
15.2.5 Key Market Developments
15.2.6 Key Strategies
15.3. Abzena Ltd
15.3.1 Overview
15.3.2 Offerings
15.3.3 Key Financials
15.3.4 Business Segment & Geographic Overview
15.3.5 Key Market Developments
15.3.6 Key Strategies
15.4 AGC Biologics 
15.4.1 Overview
15.4.2 Offerings
15.4.3 Key Financials
15.4.4 Business Segment & Geographic Overview
15.4.5 Key Market Developments
15.4.6 Key Strategies
15.5 KBI Biopharma
15.5.1 Overview
15.5.2 Offerings
15.5.3 Key Financials
15.5.4 Business Segment & Geographic Overview
15.5.5 Key Market Developments
15.5.6 Key Strategies
15.6 SE Thermo Fisher (Patheon)
15.6.1 Overview
15.6.2 Offerings
15.6.3 Key Financials
15.6.4 Business Segment & Geographic Overview
15.6.5 Key Market Developments
15.6.6 Key Strategies
15.7 LakePharma
15.7.1 Overview
15.7.2 Offerings
15.7.3 Key Financials
15.7.4 Business Segment & Geographic Overview
15.7.5 Key Market Developments
15.7.6 Key Strategies 
15.8 Genscript Biotech Corporation
15.8.1 Overview
15.8.2 Offerings
15.8.3 Key Financials
15.8.4 Business Segment & Geographic Overview
15.8.5 Key Market Developments
15.8.6 Key Strategies
15.9 Bionova Scientific
15.9.1 Overview
15.9.2 Offerings
15.9.3 Key Financials
15.9.4 Business Segment & Geographic Overview
15.9.5 Key Market Developments
15.9.6 Key Strategies
15.10 Boehringer Ingelheim BioXcellence
15.10.1 Overview
15.10.2 Offerings
15.10.3 Key Financials
15.10.4 Business Segment & Geographic Overview
15.10.5 Key Market Developments
15.10.6 Key Strategies